Tags

Type your tag names separated by a space and hit enter

Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience.
J Endourol. 2020 Aug 04 [Online ahead of print]JE

Abstract

Objective:

To analyze the long-term efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia. Materials and

Methods:

A total of 127 patients who underwent HoLEP at our institution between 2013 and 2015 were included. Patients were observed for 5 years postoperatively. We evaluated the length of the surgery, the mass of the removed tissue, prostate-specific antigen level, the maximal flow rate (Qmax), postvoid residual (PVR), the length of catheterization and hospitalization, and the International Prostate Symptom Score (IPSS) and IPSS quality of life (QoL) at each clinic visit.

Results:

PVR, Qmax, IPSS, and QoL all improved significantly immediately after the operation (p < 0.001). By the end of the 5th postoperative year, all the parameters showed a statistically meaningful decline: Qmax reduced by 5.8 mL/s (22.6%) and IPSS by 1.4 points (29.1%). Around 8.6% of the patients continued therapy with α-blockers. There were no differences in efficacy by the age of the patients or the volume of the prostate. Long-term complications and need for repeat operations were not affected by the volume of the prostate or patient age.

Conclusions:

The improvement of PVR, Qmax, IPSS, and QoL score seen in the early postoperative period after performing HoLEP remains evident at 5 years postoperatively. Long-term complications and the need for reoperation do not depend on the age of the patient or on the initial volume of the prostate.

Authors+Show Affiliations

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Institute of Linguistics and Intercultural Communication, Sechenov University, Moscow, Russia.Institute of Linguistics and Intercultural Communication, Sechenov University, Moscow, Russia.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Department of Urology, La Paz University Hospital, Madrid, Spain.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Sechenov University, Moscow, Russia.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32597216

Citation

Enikeev, Dmitry, et al. "Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: a 5-Year Single-Center Experience." Journal of Endourology, 2020.
Enikeev D, Taratkin M, Morozov A, et al. Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience. J Endourol. 2020.
Enikeev, D., Taratkin, M., Morozov, A., Singla, N., Gabdulina, S., Tarasov, A., Sukhanov, R., Rivas, J. G., Laukhtina, E., Arshiev, M., Mikhailov, V., & Glybochko, P. (2020). Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience. Journal of Endourology. https://doi.org/10.1089/end.2020.0347
Enikeev D, et al. Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: a 5-Year Single-Center Experience. J Endourol. 2020 Aug 4; PubMed PMID: 32597216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience. AU - Enikeev,Dmitry, AU - Taratkin,Mark, AU - Morozov,Andrey, AU - Singla,Nirmish, AU - Gabdulina,Svetlana, AU - Tarasov,Alexander, AU - Sukhanov,Roman, AU - Rivas,Juan Gomez, AU - Laukhtina,Ekaterina, AU - Arshiev,Magomed, AU - Mikhailov,Vasiliy, AU - Glybochko,Petr, Y1 - 2020/08/04/ PY - 2020/7/1/pubmed PY - 2020/7/1/medline PY - 2020/6/30/entrez KW - BPH KW - EEP KW - HoLEP KW - long-term JF - Journal of endourology JO - J. Endourol. N2 - Objective: To analyze the long-term efficacy and safety of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia. Materials and Methods: A total of 127 patients who underwent HoLEP at our institution between 2013 and 2015 were included. Patients were observed for 5 years postoperatively. We evaluated the length of the surgery, the mass of the removed tissue, prostate-specific antigen level, the maximal flow rate (Qmax), postvoid residual (PVR), the length of catheterization and hospitalization, and the International Prostate Symptom Score (IPSS) and IPSS quality of life (QoL) at each clinic visit. Results: PVR, Qmax, IPSS, and QoL all improved significantly immediately after the operation (p < 0.001). By the end of the 5th postoperative year, all the parameters showed a statistically meaningful decline: Qmax reduced by 5.8 mL/s (22.6%) and IPSS by 1.4 points (29.1%). Around 8.6% of the patients continued therapy with α-blockers. There were no differences in efficacy by the age of the patients or the volume of the prostate. Long-term complications and need for repeat operations were not affected by the volume of the prostate or patient age. Conclusions: The improvement of PVR, Qmax, IPSS, and QoL score seen in the early postoperative period after performing HoLEP remains evident at 5 years postoperatively. Long-term complications and the need for reoperation do not depend on the age of the patient or on the initial volume of the prostate. SN - 1557-900X UR - https://www.unboundmedicine.com/medline/citation/32597216/Long-term_outcomes_of_HoLEP:_a_5-year_single-centre_experience L2 - https://www.liebertpub.com/doi/10.1089/end.2020.0347?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.